Cancer Targeted Therapy
Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.
Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.
-
CDDO-biotin
0 ImagesCat. No.: HY-186167CAS No.: 3110422-01-7CDDO-biotin is an IKKβ inhibitor with cancer cell inhibitory activity. CDDO-biotin directly interacts with and oxidizes Cys-179 in the activation loop of IKKβ, forming an adduct with wild-type IKKβ. CDDO-biotin can be used in the research of myeloid leukemia, osteosarcoma, multiple myeloma, lung cancer, breast cancer and pancreatic cancer.
-
Anti-Mouse DR5/CD262 Antibody (MD5-1)
0 ImagesCat. No.: HY-P990249Purity: 99.20%Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer.
-
FmocNH-PEG4-t-butyl ester
0 ImagesCat. No.: HY-132064CAS No.: 2148295-94-5
-
Dasatinib carbaldehyde
0 ImagesSynonyms: BMS-354825 carbaldehyde; PROTAC ABL binding moiety 4Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .
-
Ms-PEG2-C2-Boc
0 ImagesCat. No.: HY-140383CAS No.: 1312309-62-8
-
Lewis y tetrasaccharide
0 ImagesSynonyms: Lewis yLewis Y tetrasaccharide (Lewis Y, LeY) is a tetrasaccharide derivative form of Lewis X trisaccharide (HY-N10534). Lewis Y tetrasaccharide is an antigen associated with malignant ovarian carcinomas metastasis and poor prognosis.
-
Azido-PEG9-NHS ester
0 ImagesAzido-PEG9-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG9-NHS ester is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
-
TNKS-2-IN-2
0 ImagesTNKS-2-IN-2 is a potent and selective inhibitor of TNKS2 with an IC50 of 22 nM.
-
CES2A-IN-2
0 ImagesCat. No.: HY-173267Purity: 99.16%CES2A-IN-2 (compound 14n) is an orally active, highly specific, irreversible and covalent CES2A inhibitor with an IC50 of 0.04 nM for human CES2A. CES2A-IN-2 covalently binds to CES2A by specifically targeting the catalytic serine residue (Ser-228). CES2A-IN-2 can significantly ameliorate Irinotecan-triggered gut toxicity (ITGT) without diminishing the anti-tumor effects of Irinotecan (HY-16562) in tumor-bearing mice.
-
Mitotic kinesin-IN-1 hydrochloride
0 ImagesCat. No.: HY-177246ACAS No.: 1018690-45-3Mitotic kinesin-IN-1 (Example 80) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-1 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-1 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research.
-
STAT3-IN-24, cell-permeable
0 ImagesSynonyms: PpYLKTK-mts; STAT3 PI
-
MOPIPP
0 ImagesMOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP (HY-119624). MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP can be used for the study of glioblastoma cells.
